1,2-Dihydro-1-isopropyl-2-oxo-pyrimidin | 3739-86-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 1,2-Dihydro-1-isopropyl-2-oxo-pyrimidin
• 英文别名: 2-Isopropyl-2-oxo-1,2-dihydro-pyrimidin；1-Isopropyl-pyrimidin-2-on；1-isopropyl-1H-pyrimidin-2-one；1-Isopropyl-pyrimidin-2(1H)-one；1-propan-2-ylpyrimidin-2-one
• CAS: 3739-86-4
• 化学式: C₇H₁₀N₂O
• 分子量: 138.169
• InChiKey: LIRSRODJYLUFOX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  32.7
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME
  申请人：BlinkBio, Inc.

  公开号：US20170202970A1

  公开（公告）日：2017-07-20

  Described herein are silicon based conjugates capable of delivering one or more payload moieties to a target cell or tissue. Contemplated conjugates may include a silicon-heteroatom core, one or more optional catalytic moieties, a targeting moiety that permits accumulation of the conjugate within a target cell or tissue, one or more payload moieties (e.g., a therapeutic agent or imaging agent), and two or more non-interfering moieties covalently bound to the silicon-heteroatom core.

  本文描述了基于硅的共轭物，能够将一个或多个有效载荷基团传递到靶细胞或组织。考虑到的共轭物可能包括一个硅-杂原子核心，一个或多个可选的催化基团，一个定位基团，允许共轭物在靶细胞或组织内积累，一个或多个有效载荷基团（例如，治疗剂或成像剂），以及与硅-杂原子核心共价结合的两个或更多个不干扰基团。
• FACTOR XA INHIBITORS
  申请人：Song Yonghong

  公开号：US20070259924A1

  公开（公告）日：2007-11-08

  The present invention is directed to compounds of formula (I) and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of Factor Xa. The present invention is also directed to intermediates used in making such compounds, pharmaceutical compositions containing such a compound, methods to prevent or treat a number of conditions characterized by undesired thrombosis and methods of inhibiting the coagulation of a blood sample.

  本发明涉及式(I)的化合物及其药学上可接受的盐、酯和前药，这些化合物是Xa因子的抑制剂。本发明还涉及用于制备这类化合物的中间体，含有这种化合物的药物组合物，预防或治疗一系列以不良血栓形成为特征的疾病的方法，以及抑制血样凝血的方法。
• Inhibitors of cysteine proteases and methods of use thereof
  申请人：Pardes Biosciences, Inc.

  公开号：US11124497B1

  公开（公告）日：2021-09-21

  The disclosure provides compounds with warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with warheads are provided. The compounds are contemplated to inhibit proteases, such as the 3C, CL- or 3CL-like protease. Exemplary compounds provided include Formula II-I, where R3, RB are provided herein:

  该披露提供了具有战斗头的化合物及其在治疗医学疾病或紊乱，如病毒感染方面的用途。提供了制药组合物和制备各种带有战斗头的化合物的方法。这些化合物被认为能够抑制蛋白酶，如3C、CL-或3CL样蛋白酶。提供的示例化合物包括Formula II-I，其中R3、RB如下所示：
• [EN] METHODS FOR TREATING CANCER<br/>[FR] MÉTHODES DE TRAITEMENT DU CANCER
  申请人：SCORPION THERAPEUTICS INC

  公开号：WO2022094271A1

  公开（公告）日：2022-05-05

  This disclosure provides chemical entities of formula (I) (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/ or cocrystal, and/or drug combination of the compound) that inhibit epidermal growth factor receptor (EGFR, ERBB 1) and/or Human epidermal growth factor receptor 2 (HER2, ERBB2). These chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) EGFR and/or HER2 activation contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also provides compositions containing the same as well as methods of using and making the same.

  本公开提供化学实体的公式（I）（例如，化合物或药学上可接受的盐，和/或水合物，和/或共晶体，和/或该化合物的药物组合），该化学实体可以抑制表皮生长因子受体（EGFR，ERBB1）和/或人类表皮生长因子受体2（HER2，ERBB2）。这些化学实体是有用的，例如，用于治疗某种情况，疾病或障碍，其中EGFR和/或HER2的增加（例如过度）对病理学和/或症状和/或情况，疾病或障碍的进展有贡献（例如癌症）在受试者（例如人类）中。本公开还提供包含相同物质的组合物以及使用和制备相同物质的方法。
• Potassium Channel Inhibitors
  申请人：Dinsmore J. Christoph

  公开号：US20080090794A1

  公开（公告）日：2008-04-17

  The present invention relates to compounds having the structure useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.

  本发明涉及具有以下结构的化合物，用作钾通道抑制剂，用于治疗心律失常等。